Clopidogrel
Trovati 15 articoli
- Patients with acute coronary syndrome at risk of adverse events within 3 months after stopping Clopidogrel treatment
- Patients who receive the anti-platelet medication Clopidogrel ( Plavix ) following an acute coronary syndrome appear to be at greater risk of a heart attack or death in the first 90 days after stopping Clopidogrel treatment. Randomized trials have established the effectiveness of Clopidogrel t... (Leggi Articolo)
- Coronary stents: Prasugrel may reduce ischaemic outcomes, including stent thrombosis
- Prasugrel ( Efient, Effient ), a new antiplatelet agent that provides higher levels of platelet inhibition than current standard therapies, could provide more consistent protection from ischemic events than standard treatment in patients who have had at least one coronary stent. Narrowing or b... (Leggi Articolo)
- Lack of evidence of a Clopidogrel-statin interaction
- There are conflicting data regarding whether statins predominantly metabolized by CYP3A4 reduce the metabolism of Clopidogrel ( Plavix ) to its active metabolite and diminish its clinical efficacy. CHARISMA investigators evaluated the potential impact of Clopidogrel and statin interaction in a... (Leggi Articolo)
- Primary prevention of atherothrombotic events: an excess of mortality with dual-antiplatelet therapy
- Results from the CHARISMA ( Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance ) trial showed an excess mortality in patients randomized to Clopidogrel ( Plavix ) and Acetylsalicylic acid ( Aspirin ) vs Acetylsalicylic acid alone in the prespecified ... (Leggi Articolo)
- Revised guidelines for unstable angina and non-ST-elevation myocardial infarction
- The American College of Cardiology ( ACC ) and the American Heart Association ( AHA ) have jointly released revised Guidelines for the Management of Patients with Unstable Angina and Non-ST-Elevation Myocardial Infarction. Major changes to the guidelines include: suggesting an initial non-invas... (Leggi Articolo)
- Coronary artery disease: Celecoxib after stent implantation can reduce the need for revascularisation of the target lesion
- The adjunctive use of Celecoxib ( Celebrex ) for 6 months after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion. In-vitro and animal experiments have shown that the cyclo-oxygenase 2 inhibitor Celecoxib can ... (Leggi Articolo)
- Stroke prevention in patients with non-valvular atrial fibrillation
- Clinical trials comparing antithrombotic therapy with placebo have shown that Warfarin ( Coumadin ) reduces the risk of stroke by 62%, and that Acetylsalicylic acid ( ASA, Aspirin ) alone reduces the risk by 22%. In high-risk patients, Warfarin is superior to Acetylsalicylic acid in preventi... (Leggi Articolo)
- Stopping antiplatelet drug within 30 days of receiving a drug-eluting stent raises risk of death
- Patients with myocardial infarction who stopped taking antiplatelet drugs within 30 days of receiving a drug-coated stent had nine times the risk of death compared to patients who followed doctors' orders. The study is published in the journal Circulation. " An alarming one in seven patient... (Leggi Articolo)
- Myocardial infarction: addition of Plavix to Aspirin and fibrinolytic therapy proves beneficial
- Patients whose occluded arteries were treated with standard fibrinolytic regimen, including Acetylsalicylic acid ( Aspirin ), following acute myocardial infarction with ST-segment elevation ( STEMI ) were more likely to maintain the patency of the infarct-related artery and to reduce ischemic com... (Leggi Articolo)
- Non-ST segment elevation acute coronary syndromes: better results with triple antiplatelet pre-treatment
- Aspirin and Clopidogrel ( Plavix ) are platelet antiaggregant drugs widely used and proven to be effective in the treatment of an acute coronary syndrome ( ACS ). High-risk patients with non-ST segment elevation acute coronary syndrome ( NSTE ACS ) benefit from the addition of glycoprotein ( GP ... (Leggi Articolo)
- Effient demonstrates more consistent platelet inhibition compared to Clopidogrel ( early-phase data )
- Results from three early-phase, cross-over studies demonstrated that all subjects responded to Prasugrel ( Effient ), an investigational antiplatelet agent, while 22 to 43 percent of the same subjects did not respond to Clopidogrel ( Plavix ), as measured by objectively defined parameters for inh... (Leggi Articolo)
- A clear benefit in favour of Warfarin: ACTIVE-W trial discontinued
- Study treatments for the ACTIVE W trial of the ACTIVE ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation ( Warfarin ) over antiplatel... (Leggi Articolo)
- Reduction of emboli in symptomatic carotid stenosis: Acetylsalicylic acid and Clopidogrel
- Symptomatic carotid stenosis patients are at high risk of early recurrent stroke. The CARESS ( Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis ) trial evaluated antiplatelet therapy, and the feasibility of an method based on asymptomatic microembolic signals ( M... (Leggi Articolo)
- Drug-eluting stents may cause allergic reactions
- Researchers from Northwestern Memorial Hospital have found that in some patients, the stents can cause allergic reactions that can have serious consequences. The findings have been published in the Journal of the American College of Cardiology. " This paper provides evidence for the first ... (Leggi Articolo)
- Acute coronary syndromes, adherence to treatment guidelines declines as patient age increases
- A review of more than 56,000 cases of acute coronary syndromes reveals that older patients are less likely to receive treatment recommended by guidelines, even though they benefit as much or more than younger patients when the recommended treatment is provided. " Our study is unique in that it... (Leggi Articolo)
